A one-time gene edit lowered blood fats for a year—so far

The idea is striking: instead of taking a cholesterol-lowering medicine repeatedly, receive one infusion designed to switch off a liver gene. In a first-in-human phase 1 study, 15 people whose lipid disorders were not adequately controlled by medication received CTX310, a CRISPR-Cas9 treatment targeting the gene ANGPTL3.

At the highest dose, LDL cholesterol was 52.5% lower and triglycerides were 47.8% lower than baseline after 12 months. No serious treatment-related adverse events were reported during that year. Those numbers are an intriguing early signal, especially because the edit is intended to be permanent.

But this is the moment for the large asterisk. Fifteen people is far too few to establish long-term safety, and the study was not designed to show whether the treatment prevents heart attacks or other clinical outcomes. It was funded by CRISPR Therapeutics, and extended follow-up matters especially here: unlike a medicine that can be stopped, gene editing is meant to last.